EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMMMG00000023175
Gene Symbol: HTR2A
3 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSMMMG00000001431
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSMMMG00000010115
Gene Symbol: HTR2C
3 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMMMG00000023299
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSMMMG00000023307
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSMMMG00000019045
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSMMMG00000019020
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSMMMG00000019909
Gene Symbol: HTR6
1 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSMMMG00000012295
Gene Symbol: HTR7
3 Cross references
219 Possible Orthologues:

60s Ribosomal Protein L24

Ensembl ID : ENSMMMG00000018020
Gene Symbol: LOC107152724
2 Cross references
296 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSMMMG00000020086
Gene Symbol: LOC107139231
2 Cross references
271 Possible Orthologues:

60s Ribosomal Protein L32

Ensembl ID : ENSMMMG00000005662
Gene Symbol: LOC107140623
2 Cross references
59 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).